GAM Holding AG boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 62.5% during the first quarter, HoldingsChannel reports. The firm owned 12,300 shares of the medical equipment provider’s stock after buying an additional 4,732 shares during the period. GAM Holding AG’s holdings in Hologic were worth $595,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in HOLX. American Century Companies Inc. purchased a new stake in Hologic in the fourth quarter valued at approximately $104,871,000. Norges Bank purchased a new stake in Hologic in the fourth quarter valued at approximately $75,662,000. Oregon Public Employees Retirement Fund raised its stake in shares of Hologic by 3,960.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 1,222,766 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 1,192,649 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Hologic by 1,210.3% during the first quarter. Janus Henderson Group PLC now owns 916,994 shares of the medical equipment provider’s stock worth $44,382,000 after acquiring an additional 847,011 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in shares of Hologic by 230.9% during the first quarter. Bank of Montreal Can now owns 1,089,553 shares of the medical equipment provider’s stock worth $52,734,000 after acquiring an additional 760,312 shares in the last quarter. 96.41% of the stock is currently owned by institutional investors and hedge funds.
Shares of Hologic stock opened at $48.15 on Thursday. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 1.31. Hologic, Inc. has a 52-week low of $37.47 and a 52-week high of $48.82. The company has a market capitalization of $12.80 billion, a PE ratio of 21.59, a PEG ratio of 2.21 and a beta of 0.69.
Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, May 1st. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.01. Hologic had a negative net margin of 0.32% and a positive return on equity of 26.73%. The firm had revenue of $818.40 million for the quarter, compared to analysts’ expectations of $806.99 million. During the same quarter last year, the business earned $0.53 earnings per share. The business’s revenue was up 3.7% on a year-over-year basis. As a group, analysts predict that Hologic, Inc. will post 2.42 EPS for the current year.
In other news, insider Peter J. Valenti III sold 4,545 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $44.07, for a total value of $200,298.15. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Sally Crawford sold 12,306 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $47.61, for a total transaction of $585,888.66. Following the completion of the transaction, the director now owns 168,886 shares in the company, valued at approximately $8,040,662.46. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by company insiders.
Several research analysts have commented on the stock. Zacks Investment Research downgraded shares of Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, April 10th. BidaskClub raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Friday, June 7th. TheStreet downgraded shares of Hologic from a “b” rating to a “c+” rating in a research note on Wednesday, May 1st. ValuEngine downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Finally, Needham & Company LLC reissued a “buy” rating and set a $52.00 price target (up from $50.00) on shares of Hologic in a research note on Thursday, May 2nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $45.02.
COPYRIGHT VIOLATION WARNING: “Hologic, Inc. (NASDAQ:HOLX) Position Raised by GAM Holding AG” was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://transcriptdaily.com/2019/06/13/hologic-inc-nasdaqholx-position-raised-by-gam-holding-ag.html.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Further Reading: How is diluted EPS different from basic EPS?
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.